Sign in Create account

Kilitch Drugs (India) Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: KILITCH BSE: 524500
₹233.74
▲ 15.23 (6.97%)
Oct. 5, 2026 · NSE · nse_bhavcopy
Quality
82/100
Strong
Valuation
66/100
Fairly Valued
Momentum
75/100
Bullish

QVM read Quality in motion Quality Strong, Valuation Fairly Valued, Momentum Bullish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹817 Cr
PE (TTM)
17.3
Industry median 35.6 (152 companies)
Price to Book
3.0
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
0.12%
FII + DII, latest filed period
Piotroski Score
3
Relative return vs Nifty50, qtr %
29.6
Relative return vs Sector, qtr %
23.3
Free Cash Flow
₹-76 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-51.34%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
39.94%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
22.56%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-1.47%
as of Sept. 30, 2025
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
19.90%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.83
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.32
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
19.15
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
19.45%
as of March 31, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
18.17%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
22.96%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
6.44%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
13.15%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
10.66%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

3 of 7 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • Yes Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 3)
  • Yes Debt to equity is below 0.5 (0.32)
  • No Return on equity is 15% or more (10.7%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

3 of 3 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

1 of 3 met
  • No 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

3 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Fair Value Zone)
  • No Valuation score is Undervalued (70 or more)
  • Yes Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
7.0%
Low 220.0000 · High 248.3000
1W return
7.7%
Low 207.0000 · High 248.3000
1M return
29.2%
Low 180.0000 · High 248.3000
52W return
-37.2%
Low 117.2500 · High 439.0000
Lifetime High ₹487.8500 (May 27, 2025)
Lifetime Low ₹17.1000 (June 13, 2013)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish6
Bearish0
5D
222.1
10D
215.7
20D
205.7
50D
193.9
100D
200.6
200D
229.5

Delivery and volume

Day avg. delivery
39.5%
Week avg. delivery
42.0%
Month avg. delivery
57.2%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

234.01
Pivot
First resistance248.03
Second resistance262.31
Third resistance276.33
First support219.73
Second support205.71
Third support191.43
Day RSI74.6
Day MFI72.7
Day MACD11.61
Day MACD signal9.19

Beta

1M2.03
3M1.24
1Y1.04
3Y0.81

Price change analysis

↑ 29.2%
Over 1 Month
LowHigh
180.00248.30
↑ 21.4%
Over 3 Months
LowHigh
156.00248.30
↑ 75.5%
Over 6 Months
LowHigh
122.91248.30
↓ -37.2%
Over 1 Year
LowHigh
117.25439.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 17.3 (own history: 8.3–35.3)
Fair Value Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹41 Cr
Net profit (June 30, 2026)
₹5 Cr
Basic EPS (June 30, 2026)
₹1.4500

Ranks #95 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter63.77%
  • FII/FPI0.12%
  • Public36.11%

Largest holders

NameCategoryShares %Shares
Kilitch Company (Pharma) LimitedPromoter37.9200%13258684
Bhavin Mukund MehtaPromoter14.4300%5046276
Mukund MehtaPromoter6.6100%2309294
Mira Bhavin MehtaPromoter4.8100%1682092
Dipak Kanayalal ShahPublic3.2000%1120000

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 63.77% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 0.00% to 0.12% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings were unchanged at 0.00% in Jun 2026 qtr

All shareholding details →

Insider trading, SAST & pledges

All 17 insider trades, 15 SAST, 2 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
29 Aug 2024 Mira Mehta Director Buy 0 ₹0
29 Aug 2024 Bhavin Mehta Promoter group Sell 0 ₹0
25 Apr 2022 Bhavin Mehta Promoter Buy 0 ₹0
25 Apr 2022 Mukund Mehta Promoter Sell 0 ₹0
12 Apr 2022 Mukund Mehta Promoter Buy 0 ₹0
29 Oct 2020 Bhavin Mehta Promoter Pledge 0 ₹95.55 L
29 Oct 2020 Bhavin Mehta Promoter Pledge Revoke 0 ₹1.02 Cr
1 Jul 2019 Mukund Mehta Promoter Sell 0 ₹0
1 Jul 2019 Bhavin Mehta Promoter Buy 0 ₹0
4 Sep 2018 Bhavin Mehta Promoter Buy 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 29 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
28 Oct 2025 SHRENI SHARES PVT Bulk Buy 32,332 401.8200 NSE
28 Oct 2025 SHRENI SHARES PVT Bulk Sell 117,495 405.5800 NSE
6 Mar 2018 SHAH DIPAK KANAYALAL Bulk Sell 66,699 96.3500 NSE
6 Mar 2018 BP FINTRADE PRIVATE LIMITED Bulk Buy 78,214 96.3600 NSE
6 Mar 2018 BP FINTRADE PRIVATE LIMITED Bulk Sell 56,811 98.9800 NSE
1 Mar 2018 SHAH DIPAK KANAYALAL Bulk Sell 80,000 115.8800 NSE
27 Feb 2018 RONAK BANSAL Bulk Sell 72,184 131.2800 NSE
27 Feb 2018 RONAK BANSAL Bulk Buy 72,184 122.9000 NSE
22 Jan 2018 ANKUR TUKARAM MAYEKAR Bulk Buy 150,200 85.2300 BSE
22 Jan 2018 ANKUR TUKARAM MAYEKAR Bulk Sell 150,200 85.3900 BSE

All bulk and block deals →

Dividends

Full dividend history →
Ex-dateSubjectPer share (₹)Record date
20 Sep 2019 Annual General Meeting/Dividend - Rs 0.5 Per Share 0.5000 —
18 Sep 2018 Annual General Meeting/Dividend Re 0.50 Per Share 0.5000 —
24 Sep 2012 Special Interim Dividend Rs.30/- Per Share 30.0000 25 Sep 2012
18 Aug 2011 Annual General Meeting And Dividend Re.1/- Per Share 1.0000 —
14 Oct 2010 Dividend-Re.1/- Per Share 1.0000 15 Oct 2010

Corporate Actions

Full history (17 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
24 Mar 2026BONUSBonus 1:1
15 Jul 2025RIGHTSRights 2:23 @ Premium Rs 347/-
19 Sep 2024OTHERAnnual General Meeting
21 Sep 2023OTHERAnnual General Meeting
20 Sep 2022OTHERAnnual General Meeting
21 Sep 2021OTHER Annual General Meeting

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
13 Aug 2026 Financial Results Yes
15 May 2026 Financial Results Yes
11 Feb 2026 Other business matters —
11 Feb 2026 Bonus —
11 Feb 2026 Financial Results Yes

Corporate Announcements

All 501 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
28 Sep 2026 Insider Trading / SAST Kilitch Drugs India Ltd - 524500 - Closure of Trading Window
28 Sep 2026 Trading Window Kilitch Drugs (India) Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
27 Aug 2026 Shareholders meeting Kilitch Drugs (India) Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 27, 2026
27 Aug 2026 Shareholders meeting Kilitch Drugs (India) Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 27, 2026
18 Aug 2026 Monitoring Agency Report We are submitting herewith monitoring agency report
18 Aug 2026 Copy of Newspaper Publication Kilitch Drugs (India) Limited has informed the Exchange about Copy of Newspaper Publication
13 Aug 2026 Outcome of Board Meeting Kilitch Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
4 Aug 2026 Copy of Newspaper Publication Kilitch Drugs (India) Limited has informed the Exchange about Copy of Newspaper Publication
1 Aug 2026 Updates Kilitch Drugs (India) Limited has informed the Exchange regarding 'AGM Notice and Annual Report - Physical Intimation to Shareholders'.
1 Aug 2026 Updates Kilitch Drugs (India) Limited has informed the Exchange regarding 'Intimation of Book Closure for the purpose of AGM'.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Comfortable interest coverage (19.1x)
  • Healthy liquidity (Current Ratio 1.83)
  • Strong revenue growth YoY (19.9%)

Weaknesses

  • Declining profit YoY (-1.5%)

Opportunities

Data unavailable.

Threats

  • RSI in overbought territory (74.6)
  • Down 37.2% over the past year

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Kilitch Drugs (India) Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.